
The Mexican Social Security Institute has moved to seize property and equipment from the Eli Lilly, Baxter, Fresenius Kabi, Pisa, Probiomed and Cryopharma medical laboratories. The companies have been involved in a price-fixing scheme, costing the IMSS over $660 million pesos (US $ 37.4 million) in excess charges.
“Fortunately we have been able to seize assets from several of the companies. Obviously, this has nothing to do with a subjective issue, this is in litigation, and we are guaranteeing the patrimony of the IMSS because, as established by COFECE and the Supreme Court, it was an absolute monopolistic practice “said IMSS director Mikel Arreola.
In April 2015, the Supreme Court upheld COFECE’s resolution against the pharmaceutical companies for manipulating IMSS tenders in the purchase of insulin and serums, causing a rise of up to 57.6% in prices. Since the ruling, the IMSS expects pharmacists to make reparations. The seizures seek to ensure that the laboratories comply with payment of the fines.
Full Content: El Universal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Pushes Review of CoStar’s Commercial Real Estate Antitrust Case
Jan 31, 2024 by
CPI
UK’s CMA Investigates Ardonagh’s Atlanta Group and Markerstudy Merger
Jan 31, 2024 by
CPI
Greenberg Traurig Grow Financial Regulatory and Compliance Practice
Jan 31, 2024 by
CPI
Dutch Regulator Fines Uber €10 Million for Privacy Violations
Jan 31, 2024 by
CPI
DOJ Investigates AI Competition, Eyes Microsoft’s OpenAI Deal: Bloomberg
Jan 31, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Rule(s) of Reason
Jan 29, 2024 by
CPI
Evolving the Rule of Reason for Legacy Business Conduct
Jan 29, 2024 by
CPI
The Object Identity
Jan 29, 2024 by
CPI
In Praise of Rules-Based Antitrust
Jan 29, 2024 by
CPI
The Future of State AG Antitrust Enforcement and Federal-State Cooperation
Jan 29, 2024 by
CPI